

# Foxp3 and Natural Regulatory T Cells: Key to a Cell Lineage?

## Minireview

Fred Ramsdell\*  
Celltech R&D, Inc.  
1631 220<sup>th</sup> St. SE  
Bothell, Washington 98021

The recent characterization of a mutant strain of mice generated five decades ago in a program to study ionizing radiation in mammals (and, ironically, derived from a nonmutagenized control animal) is helping to dissect a now resurgent area of immunology. Despite a vast literature during the 1970s, the study of suppressor T cells had been largely abandoned until the publication of several seminal papers rekindled interest in what are today generally referred to as regulatory T ( $T_R$ ) cells. The identification of the transcription factor **Foxp3** as the gene responsible for the defect in scurfy mice, and subsequently, the demonstration of its critical involvement in the generation of  $T_R$  cells, provides an important molecular insight into this essential cell lineage.

### Introduction

The recent interest in  $T_R$  cells follows from observations by Sakaguchi and colleagues indicating that naturally occurring  $CD4^+25^+$  T cells were capable of preventing autoimmunity *in vivo* (reviewed in Shevach, 2000). In addition to autoimmunity,  $T_R$  cells have been implicated in transplantation tolerance in rodent model systems, and *ex vivo* studies indicate that similar cells exist in humans. Despite the large number of both *in vivo* and *in vitro* studies examining  $T_R$  cell biology, there is still only a rudimentary knowledge of the molecular mechanisms that govern the development and activity of such cells.

$T_R$  cells can be delineated into two broad subsets: naturally occurring cells with suppressive activity and those that are induced following stimulation (Bluestone and Abbas, 2003; Shevach, 2002). The former are most commonly characterized by the constitutive presence of CD25, although they also express a number of other markers of activation including CD134 (OX40), GITR (TNFRSF18), CD62L (L-selectin), and CD152 (Ctla-4). These cells represent a minor (5%–10%) component of  $CD4^+$  T cells but possess potent suppressive activity both *in vivo* and *in vitro*. Using *in vitro* assays, these cells mediate their suppressive effects in a cell contact-dependent, antigen-independent manner, without the requirement of IL-10 or TGF $\beta$ . Such cells are naturally “anergic” but require stimulation via their TCR for optimal suppressive function. The mechanism by which these cells function *in vivo* is likely more complex as a role for IL-10 or TGF $\beta$  has been shown in a number of experimental systems.

Another class of  $T_R$  cells has also been described in which  $CD4^+25^-$  T cells are induced to develop regulatory

activity (Groux et al., 1997; Levings et al., 2001; Sundstedt et al., 2003; Thorstenson and Khoruts, 2001). Many different methods have been used to generate these induced (or adaptive)  $T_R$  cells, but in general, the resulting cells mediate suppression mainly through the production of suppressive cytokines such as IL-10 and TGF $\beta$ . It seems likely that these cells represent altered states of differentiation rather than a unique cell lineage. Precisely what governs the shift of  $CD4^+25^-$  T cells toward this function is unclear, although numerous pathways are implicated, including activation by immature DCs (Jonuleit et al., 2000; Wakkach et al., 2003), the presence of cytokines (IL-10) (Groux et al., 1996), and cell surface ligands (jagged-1) (Hoynes et al., 2000).

Despite the large number of papers examining  $T_R$  biology, many questions about these cells remain. What is their antigen specificity and affinity? Are there specific markers for their identification? How are these cells induced in the thymus and in the periphery? By what mechanism do they prevent disease *in vivo*? Clearly, a more detailed molecular understanding of these subsets of cells is required, and the identification of the gene responsible for disease in scurfy animals has unexpectedly provided one clue to this puzzle.

### Identification and Characterization of Foxp3

Initial studies of scurfy mice indicated that  $CD4^+$  T cells from these mice were hyperresponsive to stimulation, produced a wide variety of cytokines, and that adoptive transfer into to SCID or *nu/nu* recipients induced a rapid wasting disease (Blair et al., 1994). Overall, the phenotype resembled that of animals deficient in either CTLA-4 or TGF $\beta$ . Further, TCR transgenic scurfy animals had a greatly prolonged lifespan, suggesting that  $CD4^+$  T cell recognition of endogenous self-antigens was required for pathology. The gene responsible for disease was identified as a novel member of the forkhead/winged-helix family of transcriptional regulators and was designated Foxp3 (Brunkow et al., 2001). In addition to the forkhead domain, the protein (referred to as scurfin) also contains a single C2H2 Zinc finger and an apparent leucine-zipper motif. The gene is highly conserved in humans and appears to have a similar function because mutations within FOXP3 result in a severe autoimmune syndrome referred to as IPEX (Bennett et al., 2001; Chatila et al., 2000; Wildin et al., 2001).

Little is known about the biochemistry of scurfin. Although predicted to be a transcriptional regulator, no consensus DNA binding sequence or protein partners have been identified and it is unclear how the protein is regulated. Unlike a number of other family members, there is no PKB/AKT consensus site for phosphorylation. *In vitro* assays have indicated that scurfin can act as a transcriptional repressor using an IL-2 promoter-based reporter assay (Schubert et al., 2001), but the actual *in vivo* targets of scurfin are yet to be defined.

**Association of Foxp3 with Natural ( $CD4^+25^+$ )  $T_R$  Cells**  
A detailed study of Foxp3 mRNA indicated that expression was isolated to  $CD4^+25^+$  T cells, both in the periphery and in the thymus (Figure 1). Standard activation conditions using antibodies to the TCR and CD28 failed

\*Correspondence: fred.ramsdell@celltechgroup.com




Figure 1. A Potential Model for Foxp3 in  $T_R$  Development

Foxp3 expression occurs during thymic selection as a consequence of affinity for self-ligand or specific antigen-bearing cells. Continued expression of Foxp3 is required for natural  $T_R$  function in the periphery, and may be involved in the generation of induced  $T_R$  cells following tolerogenic stimulation of T cells.

to significantly induce Foxp3 mRNA in either  $CD4^+25^+$  or  $CD4^+25^-$  mouse cells, suggesting that this was not simply a marker of activation. This separates scurfin from other  $T_R$  “markers” such as CD25 and GITR which, although useful, are expressed more generally on activated T cells. At present, Foxp3 appears to be the gene best correlated with  $CD4^+25^+$   $T_R$  cells.

The association of Foxp3 mRNA expression with  $T_R$  cells suggested a potential functional linkage as well. The autoimmune pathologies noted in both mice and humans lacking a functional Foxp3 gene product further indicated that scurfin was involved in controlling T cell activity. To test this directly, several groups expressed Foxp3 in non- $T_R$  cells and examined their phenotype and function. Using either retroviral transduction (Fontenot et al., 2003; Hori et al., 2003) or transgenic animals (Khattry et al., 2003), overexpression of Foxp3 resulted in the acquisition of in vitro  $T_R$  activity by cells that did not (initially) express a  $T_R$  phenotype, including in one study CD8 cells. Further, the “non- $T_R$  cells” that expressed Foxp3 were capable of inhibiting disease in vivo. A substantial portion of Foxp3-bearing cells also expressed both CD25 and GITR constitutively, similar to wild-type  $T_R$  cells. Finally, in mixed bone marrow chimeras containing both Foxp3<sup>+</sup> and Foxp3<sup>null</sup> cells, it was demonstrated that all  $CD4^+25^+$   $T_R$  cells that developed were of Foxp3<sup>+</sup> origin. Thus, Foxp3 is able to control the development of  $T_R$  cells.

The data from both Hori et al. (2003) and Khattry et al. (2003) indicate that cells overexpressing Foxp3 respond

poorly to T cell stimulation compared to Foxp3-negative cells. This is true for both proliferative responses as well as cytokine production, including IL-2 and IL-10. Using cells from the mixed bone marrow chimeras, Fontenot et al. (2003) suggest that Foxp3-expressing  $CD4^+25^-$  proliferate normally to TCR stimulation. In addition, data from the latter group indicates that expression of Foxp3 correlates with increased amounts of IL-10 mRNA. Whether these differences in T cell function relate to the amount of scurfin present, the method of cell purification, or variations in in vivo differentiation is unclear at present. It should also be noted that both retrovirally transduced cells and Foxp3 transgenic cells are not as efficient at inhibition of  $CD4^+25^-$  T cell proliferation in vitro as “natural”  $CD4^+25^+$  T cells. This may be due to heterogeneity within these populations as it is impossible to determine whether all Foxp3 expressing cells also express scurfin and whether all scurfin expressing cells are in fact  $T_R$  in nature. While the presence of scurfin can clearly direct cells to the  $T_R$  lineage, there are other factors required for optimal function of these cells.

#### **Foxp3 Association with Induced ( $CD4^+25^-$ ) $T_R$ Cells**

As mentioned earlier,  $T_R$  cells can be thought of as both naturally occurring cells and those cells induced by stimulation. The mechanism of action of induced regulatory cells generally involves the production of cytokines such as IL-10 and TGF $\beta$ , a distinction from  $CD4^+25^+$  (Foxp3<sup>+</sup>) cells, and would suggest that perhaps these induced cells do not express Foxp3. Although this must be confirmed experimentally, the expression of Foxp3 may

commit cells to a natural, CD4<sup>+</sup>25<sup>+</sup> lineage whereas “induced” T<sub>R</sub> cells represent an alternative state of T cell differentiation based on the signals provided during stimulation.

FoxP3 may however, be involved in inducing another, yet to be described, population of cells to possess regulatory activity. The phenotype of animals lacking scurf in is far more dramatic than most of the experimental functions ascribed to CD4<sup>+</sup>25<sup>+</sup> T<sub>R</sub> cells in vivo. While scurfy mice succumb to their autoimmune disease within approximately 3 weeks of age, absence of T<sub>R</sub> cells results in autoimmunity, but not such a rapidly lethal phenotype. One model to explain this disparity is that the absence of scurf in during thymic development permits the “escape” of self-reactive cells possessing an affinity that would normally be diverted toward a regulatory phenotype by scurf in. The activity of such self-reactive cells might account for the dramatic pathology seen in Foxp3<sup>null</sup> animals, particularly if the generation of other (or induced) T<sub>R</sub> cells also requires the expression of Foxp3.

#### **Induction of Foxp3**

The factors that result in the induction of the Foxp3 gene, and the cell populations that can express the gene, will ultimately help to determine the mechanism(s) by which T<sub>R</sub> cells are generated. CD4<sup>+</sup>25<sup>+</sup> T<sub>R</sub> cells develop during thymic selection and Foxp3 mRNA could be controlled directly by the affinity of TCR interactions during selection. Alternately, a subset of thymic antigen-presenting cells, such as medullary thymic epithelial cells expressing AIRE, might be involved in the generation of CD4<sup>+</sup>25<sup>+</sup> T<sub>R</sub> cells. This is an attractive model as these cells are clearly involved in the generation of tolerance to tissue-specific antigens (Anderson et al., 2002; Liston et al., 2003), although there are no data to support this at present. Whether a Foxp3<sup>+</sup> subset of T<sub>R</sub> cells is also generated in peripheral tissues, and the factors that might control this, has yet to be determined.

Expression of this gene during thymic development alone is not sufficient to protect otherwise Foxp3<sup>null</sup> animals from disease (Khattri et al., 2001). This indicates that continued Foxp3 expression within peripheral tissues is necessary, either for the maintenance or the function of T<sub>R</sub> cells, for the induction of T<sub>R</sub> cells extrathymically, or for another function of scurf in that has yet to be fully characterized. Although the data for Foxp3 induction of T<sub>R</sub> activity are compelling, it is not clear whether this is the only function for the scurf in protein. CD4<sup>+</sup> T cells that overexpress scurf in are hyporesponsive to stimulation and are defective in their cytokine production, possibly accounting for their suboptimal suppressive activity. In addition, the amount of Foxp3 mRNA in transgenic mice is directly correlated with the number of peripheral T cells. This could represent the limited homeostatic expansion capacity of T<sub>R</sub> (Foxp3<sup>+</sup>) cells or a direct effect of scurf in on overall T cell expansion. Because Foxp3<sup>null</sup> and Ctla-4<sup>null</sup> mice display a very similar phenotype, it is important to note that transgenic expression of Foxp3 can dramatically delay the lethality in Ctla-4<sup>null</sup> mice, although not completely prevent disease (Khattri et al., 2003). That these Ctla-4<sup>null</sup>/Foxp3 transgenic mice possess CD4<sup>+</sup>25<sup>+</sup> T<sub>R</sub> cells suggests that these T<sub>R</sub> cells can delay disease, although there could also be a direct link between Ctla-4 signaling and

Foxp3. Unless CD4<sup>+</sup>25<sup>-</sup> peripheral T cells express scurf in following specific in vivo stimulatory conditions, the most logical model however would suggest that the primary role for scurf in is in the generation and potential maintenance of natural CD4<sup>+</sup>25<sup>+</sup> T<sub>R</sub> cells, representing a distinct T cell lineage.

#### **Concluding Thoughts**

Although the functional association of Foxp3 with T<sub>R</sub> cells provides a significant step forward in our understanding of these cells at the molecular level, there remain many questions about the mechanism by which Foxp3 exerts its effect. Whether this represents a lineage commitment gene for T<sub>R</sub> cells in a manner similar to T-bet for Th1 or GATA-3 for Th2 cells is suggested by the current data but requires further proof. Whether Foxp3 is associated with other, non-CD25<sup>+</sup> T<sub>R</sub> cells is similarly unknown, although the presence or absence of Foxp3 may help identify these subsets. Current studies will soon determine if Foxp3 is induced in any of the adaptive subsets of T<sub>R</sub> cells, and whether this correlates with their functional activity. Although the association is strong, it is nonetheless possible that Foxp3 will have functions outside that of T<sub>R</sub> biology directly, perhaps in regulating cytokine production from CD4<sup>+</sup> T cells. At the very least, the introduction of this novel gene into the landscape of lymphocyte signaling will provide a more detailed understanding of the diversification of T cell differentiation as well as a tool for the further dissection of a once nearly abandoned area of immunology.

#### **Selected Reading**

- Anderson, M.S., Venanzi, E.S., Klein, L., Chen, Z., Berzins, S.P., Turley, S.J., von Boehmer, H., Bronson, R., Dierich, A., Benoist, C., et al. (2002). *Science* 298, 1395–1401.
- Bennett, C.L., Christie, J., Ramsdell, F., Brunkow, M.E., Ferguson, P.J., Whitesell, L., Kelly, T.E., Saulsbury, F.T., Chance, P.F., and Ochs, H.D. (2001). *Nat. Genet.* 27, 20–21.
- Blair, P.J., Bultman, S.J., Haas, J.C., Rouse, B.T., Wilkinson, J.E., and Godfrey, V.L. (1994). *J. Immunol.* 153, 3764–3774.
- Bluestone, J.A., and Abbas, A.K. (2003). *Nat. Rev. Immunol.* 3, 253–257.
- Brunkow, M.E., Jeffery, E.W., Hjerrild, K.A., Paepfer, B., Clark, L.B., Yasayko, S.A., Wilkinson, J.E., Galas, D., Ziegler, S.F., and Ramsdell, F. (2001). *Nat. Genet.* 27, 68–73.
- Chatila, T.A., Blaeser, F., Ho, N., Lederman, H.M., Voulgaropoulos, C., Helms, C., and Bowcock, A.M. (2000). *J. Clin. Invest.* 106, R75–R81.
- Fontenot, J.D., Gavin, M.A., and Rudensky, A.Y. (2003). *Nat. Immunol.* 4, 330–336.
- Groux, H., Bigler, M., De Vries, J.E., and Roncarolo, M.G. (1996). *J. Exp. Med.* 184, 19–29.
- Groux, H., O’Garra, A., Bigler, M., Rouleau, M., Antonenko, S., De Vries, J.E., and Roncarolo, M.G. (1997). *Nature* 389, 737–742.
- Hori, S., Nomura, T., and Sakaguchi, S. (2003). *Science* 299, 1057–1061.
- Hoyne, G.F., Le Roux, I., Corsin-Jimenez, M., Tan, K., Dunne, J., Forsyth, L.M., Dallman, M.J., Owen, M.J., Ish-Horowicz, D., and Lamb, J.R. (2000). *Int. Immunol.* 12, 177–185.
- Jonuleit, H., Schmitt, E., Schuler, G., Knop, J., and Enk, A.H. (2000). *J. Exp. Med.* 192, 1213–1222.
- Khattri, R., Kasprowicz, D., Cox, T., Mortrud, M., Appleby, M.W., Brunkow, M.E., Ziegler, S.F., and Ramsdell, F. (2001). *J. Immunol.* 167, 6312–6320.

- Khattari, R., Cox, T., Yasayko, S.A., and Ramsdell, F. (2003). *Nat. Immunol.* **4**, 337–342.
- Levings, M.K., Sangregorio, R., Galbiati, F., Squadrone, S., de Waal, M.R., and Roncarolo, M.G. (2001). *J. Immunol.* **166**, 5530–5539.
- Liston, A., Lesage, S., Wilson, J., Peltonen, L., and Goodnow, C.C. (2003). *Nat. Immunol.* **4**, 350–354.
- Schubert, L.A., Jeffery, E., Zhang, Y., Ramsdell, F., and Ziegler, S.F. (2001). *J. Biol. Chem.* **276**, 37672–37679.
- Shevach, E.M. (2000). *Annu. Rev. Immunol.* **18**, 423–449.
- Shevach, E.M. (2002). *Nat. Rev. Immunol.* **2**, 389–400.
- Sundstedt, A., O'Neill, E.J., Nicolson, K.S., and Wraith, D.C. (2003). *J. Immunol.* **170**, 1240–1248.
- Thorstenson, K.M., and Khoruts, A. (2001). *J. Immunol.* **167**, 188–195.
- Wakkach, A., Fournier, N., Brun, V., Breitmayer, J.P., Cottrez, F., and Groux, H. (2003). *Immunity* **18**, 605–617.
- Wildin, R.S., Ramsdell, F., Peake, J., Faravelli, F., Casanova, J.L., Buist, N., Levy-Lahad, E., Mazzella, M., Goulet, O., Perroni, L., et al. (2001). *Nat. Genet.* **27**, 18–20.